Today it was reported that the President & CEO of Endocyte (ECYT), Michael A. Sherman, exercised options to buy 115,559 ECYT shares at $6.52 a share, for a total transaction value of $753.8K.
This recent transaction increases Michael A. Sherman’s holding in the company by 44.86% to a total of $9.57 million. Following Michael A. Sherman’s last ECYT Buy transaction on February 06, 2018, the stock climbed by 21.0%.
See today’s analyst top recommended stocks >>
Based on Endocyte’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $85.86K and GAAP net loss of $12.61 million. In comparison, last year the company earned revenue of $32.5K and had a GAAP net loss of $23.27 million. Currently, Endocyte has an average volume of 2.26M.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Endocyte, Inc. is a biopharmaceutical company, which engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies.
